Validation of Multimodal Evoked Potentials (mmEP) for Predicting Disease Progression in Multiple Sclerosis: Sub-study Within the Swiss Multiple Sclerosis Cohort (SMSC)

University Hospital, Basel, Switzerland3 sites in 1 country29 target enrollmentMarch 12, 2015

ConditionsMultiple Sclerosis

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Multiple Sclerosis
Sponsor: University Hospital, Basel, Switzerland
Enrollment: 29
Locations: 3
Primary Endpoint: correlation of EP-sum-score (Σ-EP) and the Expanded Disability Status Scale (EDSS)
Status: Active, not recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Utility of Multimodal Evoked potentials (mmEP) for monitoring disease course and prediction of progression at different stages of Multiple Sclerosis (MS) is investigated

Registry

clinicaltrials.gov

Start Date

March 12, 2015

End Date

July 2024

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

University Hospital, Basel, Switzerland

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•diagnosed with a clinically isolated syndrome (CIS) or MS with a relapsing-remitting (RRMS) or a primary progressive disease course (PPMS):
•CIS: EDSS \<= 5.5 within six months of first clinical event
•early RRMS: EDSS: \<= 3.5 disease course of 5 up to 10 years
•late RRMS: EDSS: 2.0-5.5 inclusive disease course of 5 to 15 years
•PPMS: EDSS: 2.0-6.5 inclusive disease course up to 15 years
•participation in the Swiss Multiple Sclerosis Cohort Study (SMSC)
•mental ability to cooperate
•written informed consent

Exclusion Criteria

•alcohol or substance abuse
•progressive disease other than Multiple Sclerosis
•psychiatric disorder requiring a treatment by a psychiatrist
•patients with movable metal implants, e.g. pace-maker, stents, deep brain stimulators etc.;(patients with jaw- or bone-fixed metal implants can be included)